Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L
Hadassah-Hebrew University School of Medicine, Jerusalem, Israel.
Ann Pharmacother. 1993 Dec;27(12):1455-7. doi: 10.1177/106002809302701207.
To report cases of manic-like behavior induced by fluvoxamine, a selective serotonin-reuptake inhibitor; to review pertinent literature; and to encourage replication of our findings in larger patient samples.
Description of a case series of fluvoxamine-induced, manic-like behavior.
Eight patients with depression or obsessive features who developed manic-like behavior after initiation of fluvoxamine therapy.
Manic symptomatology resolved in all eight patients following dosage reduction or withdrawal of fluvoxamine. Four patients still are maintained on low-dose fluvoxamine without recurrent manic symptoms.
Our case series suggests that fluvoxamine may have the ability to induce or unmask manic behavior in depressed patients. Clinicians are alerted to monitor for this "switching" effect, especially in patients previously or currently treated with neuroleptics or lithium, and in those patients exhibiting characteristics of obsessive-compulsive disorder.
报告由选择性5-羟色胺再摄取抑制剂氟伏沙明诱发的类躁狂行为病例;回顾相关文献;并鼓励在更大规模的患者样本中重复我们的研究结果。
对一系列氟伏沙明诱发的类躁狂行为病例的描述。
8例患有抑郁症或具有强迫特征的患者,在开始氟伏沙明治疗后出现类躁狂行为。
在8例患者中,随着氟伏沙明剂量的减少或停用,躁狂症状均得到缓解。4例患者仍维持低剂量氟伏沙明治疗,未再出现躁狂症状。
我们的病例系列提示,氟伏沙明可能具有诱发或暴露抑郁症患者躁狂行为的能力。临床医生应警惕监测这种“转换”效应,尤其是在既往或目前接受抗精神病药物或锂盐治疗的患者,以及那些具有强迫症特征的患者中。